Indinavir and Rifabutin Drug Interactions in Healthy Volunteers

• Published in: Journal of clinical pharmacology 2004-03, Vol.44 (3), p.305-313
• Main Authors: Kraft, Walter K., McCrea, Jacqueline B., Winchell, Gregory A., Carides, Alexandra, Lowry, Richard, Woolf, Eric J., Kusma, Sandra E., Deutsch, Paul J., Greenberg, Howard E., Waldman, Scott A.
• Format: Article
• Language: English
• Subjects: Adult; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - blood; Anti-Bacterial Agents - pharmacokinetics; antiretrovirals; Antiviral Agents - administration & dosage; Antiviral Agents - blood; Antiviral Agents - pharmacokinetics; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; HIV; Human immunodeficiency virus; Humans; Indinavir; Indinavir - administration & dosage; Indinavir - blood; Indinavir - pharmacokinetics; Male; Metabolic Clearance Rate; pharmacokinetics; rifabutin; Rifabutin - administration & dosage; Rifabutin - analogs & derivatives; Rifabutin - blood; Rifabutin - pharmacokinetics; Time Factors
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1177/0091270003262807

Two studies examined the pharmacokinetics of indinavir and rifabutin when coadministered in healthy subjects. Rifabutin, which induces the expression of cytochrome P450 (CYP) 3A, and indinavir, which inhibits that enzyme system, are frequently coadministered in patients infected with HIV. The second study was undertaken to determine if altering the dose of rifabutin coadministered with indinavir would minimize the drug interaction observed in the first study. Two studies, each with a three‐period crossover design, were performed. In study 1, standard doses of rifabutin and indinavir (300 mg of rifabutin qd and 800 mg indinavir q8h) were administered as monotherapy (with placebo to the other drug) or in combination to 10 volunteers for 10 days. In study 2, 150 mg qd of rifabutin together with 800 mg q8h of indinavir, 300 mg qd of rifabutin alone, or 800 mg q8h of indinavir alone was administered to 14 volunteers for 10 days. In study 1, the geometric mean ratio (GMR) (90% confidence interval [CI]) of the AUC(0–8h) of indinavir, coadministered with rifabutin 300 mg qd compared to indinavir alone (with rifabutin placebo), was 0.66 (0.56, 0.77), while that of the AUC(0–24h) of rifabutin, coadministered with indinavir compared to rifabutin alone (with indinavir placebo), was 2.73 (1.99, 3.77). In study 2, the GMR (90% CI) of the AUC(0–8h) of indinavir, coadministered with rifabutin 150 mg qd compared to indinavir alone, was 0.68 (0.60, 0.76), while that of the AUC(0–24h) of rifabutin, when rifabutin 150 mg qd was coadministered with indinavir compared to rifabutin 300 mg qd alone, was 1.54 (1.33, 1.79). For both studies 1 and 2, indinavir and rifabutin administered alone or in combination were generally well tolerated. No clinical or laboratory adverse experience was serious. These data demonstrate the important pharmacokinetic interactions between indinavir and rifabutin when they are coadministered. Indeed, these observations formed the basis for the subsequent ACTG 365 study that explored dose adjustments for these agents in combination regimens to preserve the sustained antiviral activity of indinavir in the absence of adverse events as a result of elevated circulating levels of rifabutin.